Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Cream in Hidradenitis Suppurativa
NCT07049575Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib cream in hidradenitis suppurativa (HS), sponsored by Incyte. Primary endpoints: Treatment-emergent Adverse Events at 24 weeks and Treatment-emergent Adverse Events leading to treatment interruption or discontinuation at 24 weeks. Started Nov 2025; status: recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07049575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049575.